Canaccord initiated coverage of Nuvalent (NUVL) with a Buy rating and $126 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent price target raised to $120 from $105 at Goldman Sachs
- Nuvalent price target raised to $132 from $114 at UBS
- Nuvalent’s Promising Drug Pipeline and Strong Financials Make It a Buy
- Nuvalent price target raised to $112 from $100 at Barclays
- Nuvalent, Inc. Reports Q3 2025 Progress and Financials